ISSN: 2231-3656

**International Journal of Pharmacy and Industrial Research (IJPIR)**

**IJPIR |Vol. 16 | Issue 3 | Jul – Sep 2026**

**www.ijpir.com**

**DOI: https://doi.org/10.61096/ijpir.v16.iss3.2026.1292.1298**

# Formulation and Characterization of Daridorexant Floating Raft-Forming In Situ Gel for Gastroretentive Drug Delivery

Author1:-RohitArunkanawade,M.Pharm,Author,2:-Dr.T.Vijaya Kumari,M.Pharm,Ph.D,Professor,Author3:-Dr.R.Narshima Rao,M.Pharm,Ph.D,Professor,Author4:Dr.N.Raghunandan,M.Pharm, Ph.D, Principal & Professor.

Holy Mary Institute of Technology and Science, College of Pharmacy Bogaram, Keesara, Medchal, Telangana, India, 501301.

Corresponding Author: ROHIT ARUN KANAWADE
Email id:rohitsantu25@gmail.com

Published on:
14.08.2026
Published by:
Futuristic Publications



**Abstract:** This study developed and evaluated a daridorexant floating raft-forming in situ gel for prolonged gastric retention and controlled nighttime drug delivery. Six formulations, DRG1–DRG6, were prepared using sodium alginate, calcium carbonate, sodium bicarbonate and Tween 80. The formulations were assessed for appearance, pH, viscosity, gelation time, raft strength, floating lag time, total floating duration, drug content, in vitro release, release kinetics and accelerated stability. Increasing sodium alginate and calcium carbonate concentrations improved gelation, raft strength and buoyancy while slowing drug release. DRG4 showed the most balanced performance, with pH 7.26 ± 0.03, viscosity 428.2 ± 19.4 mPa·s, gelation time 31 ± 2 s, raft strength 8.12 ± 0.48 g, floating lag time 28 ± 2 s, drug content 99.18 ± 1.16% and 94.18% release at 12 h. Release followed the Korsmeyer-Peppas model, indicating anomalous transport. DRG4 remained stable for three months under accelerated conditions without meaningful changes in performance parameters.

**Keywords:** Daridorexant, raft-forming in situ gel, gastroretentive delivery, sodium alginate, controlled release, insomnia, buoyancy.

## INTRODUCTION

Insomnia is a common sleep disorder characterized by difficulty initiating sleep, maintaining sleep, or obtaining restorative sleep. Pharmacological therapy is used when symptoms are persistent and clinically relevant, but dosage-form design remains important because drug release, gastrointestinal residence, and administration time can influence pharmaceutical performance [1–4].

Daridorexant is a dual orexin receptor antagonist developed for insomnia. It reduces wake-promoting orexin signalling and is administered orally. Although the drug is already available as an oral

dosage form, a gastroretentive formulation can be investigated as a formulation strategy to prolong gastric residence and provide controlled nighttime release rather than as proof of superior clinical efficacy [5–8].

Gastroretentive drug-delivery systems are intended to remain in the stomach longer than conventional dosage forms. Floating and raft-forming systems achieve this by generating or entrapping gas within a hydrated polymeric matrix, thereby reducing apparent density and prolonging buoyancy. Their performance depends on polymer concentration, gas generation, gel strength, gastric fluid availability, and the ability of the matrix to remain sufficiently coherent during drug release [9–12].

Sodium alginate is widely used in raft-forming formulations because it rapidly hydrates and forms gels in the presence of calcium ions. Calcium carbonate can provide calcium for gel formation and also contribute to gas generation in acidic medium, while sodium bicarbonate supports buoyancy. The balance among viscosity, gelation time, raft strength, floating lag, and drug release is therefore critical; excessive polymer may improve raft strength but reduce pourability and retard drug release [13–16].

Previous studies on alginate-based floating and raft-forming systems support the feasibility of this approach for gastroretentive delivery [17–20]. Accordingly, the present study formulated six daridorexant raft-forming in situ gels and evaluated their physicochemical properties, buoyancy, raft characteristics, drug content, in vitro release, and short-term accelerated stability.

## MATERIALS AND METHODS

### Chemicals

Deridorexant was obtained from Gift sample from Unichem laboratories Ltd., Mumbai. Sodium alginate was obtained from Global Exports Private Ltd., Mumbai. Tween 80 was obtained from Global Exports Private Ltd., Mumbai. Sodium bicarbonate was obtained from S.D. FineChem Limited, Mumbai. Calcium carbonate was obtained from S.D. FineChem Limited, Mumbai.

### Preformulation and analytical studies

Daridorexant was subjected to routine preformulation testing, UV analysis at 271 nm, and compatibility assessment with the selected polymer. The calibration relationship was used for quantitative estimation.

### Formulation design

Six formulations, DRG1–DRG6, were prepared with a constant daridorexant dose while sodium alginate and calcium carbonate concentrations were varied. Sodium bicarbonate and Tween 80 were maintained according to the formulation matrix.

**Table 1:** Formulation composition of daridorexant raft-forming in situ gels

| Formulation | DRX | Sodium alginate | Calcium carbonate | Sodium bicarbonate | Tween 80 | Purified water q.s. |
|---|---|---|---|---|---|---|
| DRG1 | 25 | 1.00 | 0.50 | 0.50 | 0.10 | 10 mL |
| DRG2 | 25 | 1.00 | 0.75 | 0.50 | 0.10 | 10 mL |
| DRG3 | 25 | 1.25 | 0.50 | 0.50 | 0.10 | 10 mL |
| DRG4 | 25 | 1.25 | 0.75 | 0.50 | 0.10 | 10 mL |
| DRG5 | 25 | 1.50 | 0.50 | 0.50 | 0.10 | 10 mL |
| DRG6 | 25 | 1.50 | 0.75 | 0.50 | 0.10 | 10 mL |

Note: All ingredients are in mg.

### Preparation method

Sodium alginate was gradually dispersed in purified water and allowed to hydrate. Daridorexant was triturated with Tween 80 and a small quantity of water and incorporated into the hydrated alginate. Calcium carbonate and sodium bicarbonate were then dispersed under gentle stirring, and the final volume was adjusted with purified water. The same procedure was used for all six batches, with only the specified formulation variables changed.

### FTIR compatibility study

FTIR spectra of pure daridorexant, sodium alginate, and the optimized formulation were recorded over 4000–400 $cm^{-1}$ and compared for retention, shifting, broadening, appearance, or disappearance of characteristic bands.

### Evaluation

The formulations were evaluated for appearance, pH, viscosity, gelation time, raft strength, floating lag time, total floating duration, and drug content. These parameters were used to assess pourability before administration and formation of a coherent floating raft after contact with acidic medium.

### In vitro drug release

In vitro release was evaluated in 0.1 N HCl at pH 1.2 under the paddle conditions reported in the thesis, with sampling continued for 12 h and daridorexant quantified spectrophotometrically.

### Stability study

The optimized formulation was stored at 40 ± 2°C/75 ± 5% RH for three months and reassessed for the principal physical and release characteristics.

## RESULTS AND DISCUSSION

### Drug-excipient compatibility

The major characteristic bands of daridorexant were retained in the optimized formulation with limited shifts and spectral overlap. No unexpected new major band was reported, supporting the absence of a major chemical incompatibility with sodium alginate.

**Table 2**: Comparative FTIR peak assignments of daridorexant, sodium alginate, and optimized formulation

| **Functional group** | **Pure Deridorexant ($cm^{-1}$)** | **Sodium alginate ($cm^{-1}$)** | **Optimized formulation ($cm^{-1}$)** |
|---|---|---|---|
| O–H / N–H stretching region | 3295 | 3420 | 3392 |
| Aliphatic C–H stretching | 2928 | 2927 | 2928 |
| Carbonyl stretching region | 1712 | – | 1710 |
| Carbonyl or aromatic associated region | 1654, 1602 | 1603 | 1622 |
| CH bending / carboxylate region | 1496 | 1415 | 1414 |
| C–O / C–N fingerprint region | 1258, 1170, 1108 | 1095, 1030 | 1250, 1092, 1032 |
| Aromatic out-of-plane region | 760 | – | 760 |




**Fig 1:** FTIR spectrum of pure daridorexant.




**Fig 2:** FTIR spectrum of sodium alginate.




**Fig 3:** FTIR spectrum of the optimized formulation.

## Physicochemical and raft-forming properties

All six batches were uniform without visible phase separation. Increasing sodium alginate and calcium carbonate increased viscosity and raft strength while shortening gelation and floating lag time. Drug content remained within the reported acceptable range. DRG4 provided a balanced combination of pourability, gelation, raft strength, and buoyancy.

**Table 3:** Appearance, pH, viscosity, gelation time, and raft strength

| Batch | Appearance | pH | Viscosity (mPa·s) | Gelation time (s) | Raft strength (g) |
|---|---|---|---|---|---|
| DRG1 | Uniform whitish dispersion | 7.18 ± 0.04 | 284.6 ± 12.8 | 52 ± 3 | 4.86 ± 0.31 |
| DRG2 | Uniform whitish dispersion | 7.21 ± 0.05 | 296.4 ± 14.2 | 44 ± 2 | 5.72 ± 0.36 |
| DRG3 | Smooth viscous dispersion | 7.24 ± 0.04 | 412.8 ± 18.6 | 39 ± 2 | 6.84 ± 0.42 |
| DRG4 | Smooth viscous dispersion | 7.26 ± 0.03 | 428.2 ± 19.4 | 31 ± 2 | 8.12 ± 0.48 |
| DRG5 | Thick uniform dispersion | 7.29 ± 0.05 | 562.6 ± 24.8 | 34 ± 2 | 8.46 ± 0.51 |
| DRG6 | Thick uniform dispersion | 7.31 ± 0.04 | 578.4 ± 26.2 | 26 ± 2 | 9.38 ± 0.57 |

**Table 4:** Floating behaviour and drug content

| Batch | Floating lag time (s) | Total floating time (h) | Drug content (%) |
|---|---|---|---|
| DRG1 | 58 ± 4 | 7.2 ± 0.4 | 96.84 ± 1.42 |
| DRG2 | 46 ± 3 | 8.6 ± 0.5 | 97.26 ± 1.36 |
| DRG3 | 39 ± 3 | 9.8 ± 0.6 | 98.12 ± 1.28 |
| DRG4 | 28 ± 2 | 11.7 ± 0.5 | 99.18 ± 1.16 |
| DRG5 | 34 ± 3 | 10.9 ± 0.6 | 98.46 ± 1.31 |

| | | | |
|---|---|---|---|
| DRG6 | 24 ± 2 | >12 | 98.72 ± 1.24 |

**In vitro drug release and optimized formulation**

Drug release decreased as the raft-forming matrix became stronger. Lower-polymer batches released daridorexant more rapidly, whereas higher-polymer formulations produced greater release retardation. DRG4 showed pH 7.26 ± 0.03, viscosity 428.2 ± 19.4 mPa·s, gelation time 31 ± 2 s, raft strength 8.12 ± 0.48 g, floating lag time 28 ± 2 s, drug content 99.18 ± 1.16%, and 94.18% release at 12 h. It was therefore selected as the optimized batch.




**Fig 4:** In vitro drug-release profiles of daridorexant raft-gel formulations.

**Stability study**

DRG4 remained physically stable during three months of accelerated storage, with no visible separation or precipitation and only minor changes in pH, viscosity, drug content, and release.

## CONCLUSION

Daridorexant floating raft-forming in situ gels were successfully prepared using sodium alginate with calcium carbonate and sodium bicarbonate. Polymer and calcium levels influenced viscosity, gelation, raft strength, buoyancy, and release. DRG4 showed the most balanced overall performance and released 94.18% of daridorexant over 12 h while remaining pourable before gelation. The formulation also retained acceptable characteristics during the three-month accelerated study.

## REFERENCES

1. Mayavanshi AV, Gajar SS. Floating drug delivery system to increase gastric retention of drug: A Review .J. Pharm.Res., Oct- dec .2008: 1940:345-348.
2. St. Onge E, et al. Daridorexant: a new dual orexin receptor antagonist for insomnia. Ann Pharmacother / review article. 2022.
3. St. Onge E, Phillips B, Rowe C. Daridorexant: a new dual orexin receptor antagonist for insomnia. Journal of Pharmacy Technology. 2022.
4. Gehin M, Wierdak J, Sabattini G, Sidharta PN, Dingemanse J. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of Daridorexant, a dual orexin receptor antagonist. British Journal of Clinical Pharmacology. 2022; 88(2):810–819. doi:10.1111/bcp.15029.
5. DailyMed / QUVIVIQ® Healthcare Professional Information. Daridorexant prescribing information.

6. Martha S, Shalini G, Priyanka M, Kamalika S, Uddin MM, Krishna YR, et al. Formulation, development and in vitro evaluation of Daridorexant immediate release tablets. High Technology Letters. 2022; 28(8):98–111. doi:10.37896/HTL28.08/6310.
7. Stability indicating UV spectroscopic method development and validation of Daridorexant in API and its prepared pharmaceutical dosage form. International Journal of Drug Delivery Technology. 2026; 16(12s):679.
8. Stability-indicating UV spectroscopic method development and validation of Daridorexant in API and dosage form. International Journal of Drug Delivery Technology. 2026;16(12s):679.
9. Awasthi, R. FLOATING IN-SITU RAFT FORMING LIQUID GASTRORETENTIVE DRUG DELIVERY SYSTEM CONTAINING POORLY WATER-SOLUBLE DRUG. Bulletin of Pharmaceutical Sciences Assiut University, 2021; 44(2): 301-312. doi: 10.21608/bfsa.2021.207147
10. El Nabarawi, M. A., Teaima, M. H., Abd El-Monem, R. A., El Nabarawy, N. A., & Gaber, D. A. (2017). Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. Drug design, development and therapy, 11, 1081–1093. https://doi.org/10.2147/DDDT.S131936
11. Awasthi, R. FLOATING IN-SITU RAFT FORMING LIQUID GASTRORETENTIVE DRUG DELIVERY SYSTEM CONTAINING POORLY WATER-SOLUBLE DRUG. Bulletin of Pharmaceutical Sciences Assiut University, 2021; 44(2): 301-312. doi: 10.21608/bfsa.2021.207147
12. El Nabarawi, M. A., Teaima, M. H., Abd El-Monem, R. A., El Nabarawy, N. A., & Gaber, D. A. (2017). Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. Drug design, development and therapy, 11, 1081–1093. https://doi.org/10.2147/DDDT.S131936
13. Kim H. M. (2016). Raft Formation of Sodium Alginate in the Stomach. Journal of neurogastroenterology and motility, 22(4), 705–706. https://doi.org/10.5056/jnm16068
14. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14(6):669-690. doi:10.1046/j.1365-2036.2000.00759.x
15. Kim H. M. (2016). Raft Formation of Sodium Alginate in the Stomach. Journal of neurogastroenterology and motility, 22(4), 705–706. https://doi.org/10.5056/jnm16068
16. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14(6):669-690.
17. Dorwal D, Gupta R. Formulation and Characterization of Novel Floating Raft Forming In-situ Gel for Delivery of BCS Class II Drugs. J Neonatal Surg [Internet]. 2025Mar.4 [cited 2025Oct.18]; 14(4S):1133-50. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/1924
18. Rajmane A, Trivedi R, Nandgude T. Formulation and evaluation of raft forming pirenzepinedihydrochloride floating tablets for peptic ulcer. Int. J. of Health Sci. [Internet]. 2022 Jun. 3 [cited 2025 Oct. 18]; 6(S3):10558-74. Available from: https://sciencescholar.us/journal/index.php/ijhs/article/view/8360
19. Yerikala R, Pudi VP, Saravanakumar K, Vadhireddy S. Formulation and evaluation of floating drug delivery of cefotaxime using raft forming approach. J. Drug Delivery Ther. [Internet]. 2017 Jul. 15 [cited 2025 Oct. 18]; 7(4):110-9. Available from: https://jddtonline.info/index.php/jddt/article/view/1473
20. Research reports on sodium alginate-based floating oral in situ gels using 0.1 N HCl, pH 1.2, 37 ± 0.5 °C and USP Type II paddle apparatus. Research Journal of Pharmacy and Technology. 2019.